Clinical Trial Update: Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluated the anti-inflammatory effects of Agaricus blazei Murill in inflammatory bowel disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Agaricus blazei Murill

Snippet

Sponsor: Oslo University Hospital | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 2, Phase 3 | Status: COMPLETED